The findings should encourage dermatologists to consider incorporating GLP-1s into treatment plans when managing HS, Barbieri said, especially for patients with recalcitrant disease and those for whom weight loss is a goal to improve disease severity and quality of life
That said, peptide therapy is not for everyone
The overall cardiometabolic benefit of GLP-1RA rapidly expanded beyond the T2DM population, with the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial describing MACE reduction in the population with overweight and obesity, even in the absence of T2DM [14]
Essentially all administered LR3 remains free and receptor-available
GLP-1 medications such as Ozempic and Wegovy, which help people lose large amounts of weight and maintain their weight loss, have been one of the biggest cost-drivers in our system, state Secretary of Human Services Dr